详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

CAR-T therapy for endocrine neoplasms: novel targets and combination of therapies

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Otolaryngology-Head and Neck Surgery, Xinyang Central Hospital, Xinyang, Henan, China. [2]Department of Urology, First Affiliated Hospital of Zhengzhou University, Henan Joint International Pediatric Urodynamic Laboratory, Zhengzhou, China. [3]Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. [4]Department of Pharmacology, Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, China. [5]Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. [6]Department of Lung Cancer, Tianjin Lung Cancer Center, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. [7]Department of Ultrasound, Xinyang Central Hospital, Xinyang, Henan, China. [8]Department of Gastroenterology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. [9]Department of Gynaecology, Xinyang Central Hospital, Xinyang, Henan, China.

出处：

DOI：

ISSN：

关键词： endocrine neoplasms chimeric antigen receptor T cell immunotherapy combined immunotherapy clinical trials

摘要：

Endocrine malignancies constitute a heterogeneous tumour group with diverse biological characteristics. While typically indolent, they encompass aggressive types and presence of any metastatic sign indicates a high probability of recurrence and a diminished response to conventional therapies. Chimeric antigen receptor (CAR)-T cell immunotherapy has constituted a revolutionary advance in cancer treatment and exhibited significant potential for application in endocrine cancer. However, limited effectiveness was displayed in clinical application, which necessitates the exploration of novel modalities. Identification of specific and safe targets for endocrine cancer is the initial stage towards establishing a successful CAR-T treatment. Various therapies under investigation offer potential enhancements to CAR T cell efficacy through diverse mechanisms. Herein, we summarize recent advances in identifying targets of endocrine cancer for CAR therapy and provide an overview of combinatorial approaches.Copyright © 2025 Wang, Zhang, Zhou, Shi, Peng, Xu, Yang, Wang, Zhang, Tu, Zhang, Liu and Cai.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版：

无

最新[2023]版：

大类 | 2 区医学

小类 | 2 区内分泌学与代谢

第一作者：

第一作者机构： [1]Department of Otolaryngology-Head and Neck Surgery, Xinyang Central Hospital, Xinyang, Henan, China.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

CAR-T therapy for endocrine neoplasms: novel targets and combination of therapies

文献详情

相关文献